Ixekizumab

Ixekizumab demonstrated significantly greater joint and skin improvement, through week 52, than adalimumab among patients with psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.

Treatment with IL-17 inhibitors significantly increases response rates among patients with ankylosing spondylitis, but with an increased risk for non-severe infections, according to a meta-analysis published in Arthritis Research & Therapy.

Long-term clinically significant and sustained improvements were seen with ixekizumab treatment in patients with moderate to severe plaque psoriasis, according to a study reported at the American Academy of Dermatology virtual meeting.

The FDA has expanded the approval of ixekizumab injection 80 mg/mL to include treatment of active nonradiographic axial spondyloarthritis in patients with objective signs of inflammation.

A dose reduction schedule of biologics did not show noninferiority to the standard of care based on Psoriasis Area and Severity Index; however, quality of life scores did show noninferiority, according to a clinical trial.

Ixekizumab may reduce signs and symptoms of pityriasis rubra pilaris in some patients.

The FDA has approved a supplemental biologics license application for ixekizumab in pediatric patients with moderate to severe plaque psoriasis, according to a press release from Eli Lilly.

Several novel treatments for moderate to severe plaque psoriasis were associated with the highest Psoriasis Area and Severity Index response rates, according to a comprehensive assessment of efficacy published in JAMA Dermatology.

Taltz was found to be more effective at improving signs and symptoms among patients with moderate to severe plaque psoriasis than Tremfya, according to a multicenter, randomized, double-blind, parallel-group, phase 4 study.

Both ixekizumab and brodalumab were associated with better clinical benefit than other biologic therapies over 12 weeks or 16 weeks of treatment for psoriasis, according to a meta-analysis.